Lixte Biotechnology Holdings, INC Form 4 insider transactions

Lixte Biotechnology Holdings, Inc. reports that Chief Financial Officer Peter Stazzone received 50,000 restricted stock units (RSUs) on July 1, 2026, vesting upon achievement of performance conditions.

Lixte Biotechnology Holdings, Inc. CEO Geordan Pursglove was granted 350,000 restricted share units (RSUs) that have vested upon achievement of performance conditions.

Lixte Biotechnology Holdings, Inc. Director Guy Primus received 15,000 restricted share units (RSUs) that have vested.

Michael Holloway, a Director at Lixte Biotechnology Holdings, Inc., received 15,000 restricted share units (RSUs) that have vested.

Lixte Biotechnology Holdings, Inc. reports that Director Lourdes Felix was granted 30,000 restricted share units (RSUs) that have vested.

Lixte Biotechnology Holdings, Inc. reports that Director Stuart D. Porter was granted 25,000 restricted stock units (RSUs) on May 29, 2026, vesting over time.

CEO and Chairman Geordan Pursglove exchanged 350,000 stock options for 350,000 immediately vesting restricted share units.

Lixte Biotechnology CFO Peter Stazzone exchanged 50,000 stock options for 50,000 immediately vesting restricted share units.

Director Lourdes Felix exchanged 25,000 stock options for 25,000 fully vested restricted share units.

Director Jason David Sawyer exchanged 25,000 stock options for 25,000 fully vested restricted share units.

Director Michael Andrew Holloway exchanged 25,000 stock options for 25,000 fully vested restricted share units.

Director Guy Primus exchanged 25,000 stock options for 25,000 immediately vesting restricted share units.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Director Guy Warren Primus acquired 25,000 stock options with an exercise price of $4.05, vesting over time.

Lourdes Felix, a director at Lixte Biotechnology Holdings, Inc., was granted 25,000 stock options with an exercise price of $4.05.

Lixte Biotechnology Holdings' Chief Financial Officer, Peter Stazzone, received a grant of 50,000 stock options with an exercise price of $4.45 per share.

Lixte Biotechnology Holdings, Inc. director Jason David Sawyer was granted 25,000 stock options with an exercise price of $3.59 per share, effective August 15, 2025.

LIXTE Biotechnology Holdings, Inc. Director Michael Holloway received 25,000 stock options with an exercise price of $3.59 per share, vesting over time.

LIXTE Biotechnology Holdings, Inc. CEO and Chairman, Geordan Garrett Pursglove, was granted 350,000 stock options as a signing bonus for an employment agreement.

Lixte Biotechnology Holdings, Inc. Director Yun Yen was granted 21,632 stock options, with 11,632 vesting immediately in lieu of cash compensation, aligning executive interests with shareholder value.

Lixte Biotechnology Holdings, Inc. director Stephen J. Forman was granted new stock options, including a portion immediately vesting in exchange for quarterly cash compensation.

LIXTE Biotechnology Holdings, Inc. Director Regina Brown was granted 22,600 new stock options, with 12,600 vesting immediately in lieu of cash compensation and 10,000 vesting quarterly over two years.

Lixte Biotechnology Holdings, Inc. Director Rene Bernards reported the acquisition of 20,662 new stock options, with 10,662 vesting immediately in lieu of cash compensation and 10,000 vesting quarterly.

Director Stephen J. Forman acquired 5,851 options to purchase common stock in Lixte Biotechnology Holdings, Inc. in lieu of quarterly cash compensation.

Director Regina Brown acquired 9,508 stock options in Lixte Biotechnology Holdings, Inc. on March 31, 2025, in lieu of quarterly cash compensation.

Director Yun Yen received 8,777 stock options in Lixte Biotechnology in lieu of quarterly cash compensation on March 31, 2025.

Director Rene Bernards acquired 8,045 shares of Lixte Biotechnology through stock options granted in lieu of quarterly cash compensation.

Director Stephen Forman of Lixte Biotechnology Holdings, Inc. was granted 3,030 stock options on January 20, 2025, in lieu of quarterly cash compensation.

Director Yun Yen of Lixte Biotechnology Holdings, Inc. acquired 4,545 shares through stock options as part of their board compensation.

Regina Brown, a director at Lixte Biotechnology Holdings, Inc., received 4,924 stock options in lieu of cash compensation.

Lixte Biotechnology Holdings director, Rene Bernards, received stock options in lieu of cash compensation, according to a recent SEC filing.